177Lu是一种治疗性核素,而激素治疗可增加PSMA的表达和放射敏感性。因此在这项由美国国防部资助的研究中,我们假设177Lu-J591与酮康唑(keto)和氢化可的松(HC)联用靶向PSMA治疗非转移性去势抵抗性前列腺癌(nmCRPC),可获得较111In更好...
A phase II trial of single-dose 177Lu-J591 radioimmunotherapy (RIT) in pts with progressive, metastatic castration-resistant prostate cancer (CRPC) demonstrated excellent targeting of metastatic sites, efficacy, and acceptable toxicity (Tagawa et al, ASCO 2008). In general, RIT appears to have ...
Radioimmunotherapy of metastatic prostate cancer with 177Lu-DOTAhuJ591 anti prostate specific mem- brane antigen specific monoclonal antibody. Curr Radiopharm. ... S Vallabhajosula,A Nikolopoulou,Y Jhanwar,... 被引量: 7发表: 2016年 952 ANTI-PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)-BASED RADIOIMMU...
177Lu是一种治疗性核素,而激素治疗可增加PSMA的表达和放射敏感性。因此在这项由美国国防部资助的研究中,我们假设177Lu-J591与酮康唑(keto)和氢化可的松(HC)联用靶向PSMA治疗非转移性去势抵抗性前列腺癌(nmCRPC),可获得较111In更好的无转移生存期(MFS)。 方法:前列腺特异性抗原倍增时间(PSADT)<8个月和/或PSA>...